Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) are an emerging therapy for dyslipidemia. Acute coronary events induce a dynamic increase of PCSK9 levels that may play a role in plaque vulnerability of both culprit and nonculprit coronary vessels. Growing evidence highlights a potential key role of PCSK9 antibodies in managing acute coronary syndrome. This review describes the influence of PCSK9 antibodies on plaque composition and instability, as well as the pharmacokinetic profile and the potential anti-inflammatory and antithrombotic mechanisms associated with PCSK9 inhibition that may confer benefits during the early phase of acute coronary syndrome. The authors posit a rationale for the use of PCSK9 antibodies in patients with acute coronary syndrome and highlight the need for further investigation in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Colesevelam can also reduce glucose levels in hyperglycaemic patients [275].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [275]
In the citing paper
“A recent meta-analysis confirmed these findings.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [249]
In the citing paper
“A recent meta-analysis confirmed these findings.249”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [249]
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The Nuclear Factor NF- B Pathway in Inflammation
Lawrence, T. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001651 · Cited by 4,898
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,276
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“The reduction in myocardial infarction seen in a recent meta-analysis and in higher-risk patients enrolled in the ODYSSEY LONG TERM (Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy) trial support…”
BackgroundAn endothelial receptor for oxidized low-density lipoprotein
Sawamura, T., Kume, N., Aoyama, T., Moriwaki, H., Hoshikawa, H., Aiba, Y., Tanaka, T., Miwa, S., Katsura, Y., Kita, T., et al. (1997) · Nature · doi:10.1038/386073a0 · Cited by 1,385 · cited 1×
“crease in oxLDL uptake, production of cell-surface adhesion molecules, and a state of oxidative stress and inflammation—2 key steps involved in the progression of atherosclerosis and destabilization of coronary plaque (32).”
BackgroundEhara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1955 · Cited by 781 · cited 1×
“Atherosclerotic plaque destabilization and rupture may be influenced by oxLDL, which induces the expression of molecules on endothelial cells that promote adhesion of monocytes (33).”
BackgroundLack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice
Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H., & Seishima, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000064374.15232.c3 · Cited by 748
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Podrez, E. A., Byzova, T. V., Febbraio, M., Salomon, R. G., Ma, Y., Valiyaveettil, M., Poliakov, E., Sun, M., Finton, P. J., Curtis, B. R., et al. (2007) · Nature Medicine · doi:10.1038/nm1626 · Cited by 513
Research works printed but not linked: 1
- Virmani R, 1999, Thromb Haemost, 82, 1
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Early preliminary data from phase III trials suggests a reduction of CV events in line with the LDL-C reduction achieved.(286,290,291) Recently, two major studies were completed: the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) and the Evaluation of Cardiovasc…”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Qi, Z., Hu, L., Zhang, J., Yang, W., Liu, X., Jia, D., Yao, Z., Chang, L., Pan, G., Zhong, H., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046290 · Cited by 268
Bonicalzi, M.-È., Haince, J.-F., Droit, A., & Poirier, G. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4505-1 · Cited by 171
Interaction between platelets and endothelium: from pathophysiology to new therapeutic options
Hamilos, M. I., Petousis, S., & PARTHENAKIS, F. I. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.07.01 · Cited by 155
Navarese, E. P., Kołodziejczak, M. M., Winter, M., Alimohammadi, A., Lang, I. M., Buffon, A., Lip, G. Y. H., & Siller-Matula, J. M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.084 · Cited by 140
Self-citationAtar, D., Jukema, J. W., Molemans, B., Taub, P. R., Goto, S., Mach, F., Olmos, C. C., Underberg, J. A., KEECH, A. C., Tokgözoğlu, L. S., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.12.013 · Cited by 90
Pastori, D., Nocella, C., Farcomeni, A., Bartimoccia, S., Santulli, M., Vasaturo, F., Carnevale, R., Menichelli, D., Violi, F., Pignatelli, P., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.743 · Cited by 81
Low-density lipoprotein cholesterol lowering treatment: the current approach
Crîşmaru, I., Stoian, A. P., Bratu, O. G., Găman, M., Stănescu, A. M. A., Bacalbaşa, N., & Diaconu, C. C. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01275-x · Cited by 76
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure
Bayés‐Genís, A., Núñez, J. E., Zannad, F. M., Ferreira, J. P., Anker, S. D., Cleland, J. G. F., Dickstein, K., Filippatos, G. S., Lang, C. C., Ng, L. L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.057 · Cited by 61
Pleiotropic Effects of PCSK-9 Inhibitors
Basiak, M., Kosowski, M., Cyrnek, M., Bułdak, Ł., Maligłówka, M., Machnik, G., & Okopień, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063144 · Cited by 60
Zanchin, C., Koskinas, K. C., Ueki, Y., Losdat, S., Häner, J. D., Bär, S., Otsuka, T., Inderkum, A. P., Jensen, M. D. R. J., Lønborg, J., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.04.006 · Cited by 43
Bae, K.-H., Kim, S. W., Choi, Y., Seo, J. B., Kim, N., Kim, C., Lee, W. K., Lee, S., Kim, J. G., Lee, I., et al. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.0081 · Cited by 42
New directions for pharmacotherapy in the treatment of acute coronary syndrome
Adamski, P., Adamska, U., Ostrowska, M., Koziński, M., & Kubica, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241234 · Cited by 37
Ziogos, E., Chelko, S. P., Harb, T., Engel, M., Vavuranakis, M., Landim-Vieira, M., Walsh, E. M., Williams, M. S., Lai, S., Halushka, M. K., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad051 · Cited by 36
Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
Bittner, V. (2016) · Circulation · doi:10.1161/circulationaha.116.023687 · Cited by 31
Zhang, Z., Wei, T., Zhao, B., Yin, Z. F., Shi, Q., Liu, P., Liu, L., Liu, L., Zhao, J., Mao, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-35773-x · Cited by 31
Bellis, A., Gioia, G. D., Mauro, C., Mancusi, C., Barbato, E., Izzo, R., Trimarco, B., & Morisco, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132968 · Cited by 29
Ferreira, J. P., Xhaard, C., Lamiral, Z., Borges‐Canha, M., Neves, J. S., Dandine‐Roulland, C., Floch, É. L., Deleuze, J., Bacq‐Daian, D., Bozec, E., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014758 · Cited by 29
“We also tested the association of the genetic alleles on top of the clinical model plus PCSK9 and LDLR.”
BackgroundInfluentialDurairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
Szymański, F. M., Barylski, M., Cybulska, B., Wożakowska−Kapłon, B., Krasiński, Z., Mamcarz, A., Widecka, K., Platek, A. E., Dudek, D., Mickiewicz, A., et al. (2018) · Cardiology Journal · doi:10.5603/cj.2018.0141 · Cited by 32
Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23112 · Cited by 26
“The PCSK9 enzyme is expressed in atherosclerotic plaques,(16) implicated in vascular inflammation,(17) and may affect platelet function and thrombogenicity according to preclinical evidence.(18) Whether these mechanistic effects might translate to”
BackgroundTian, W., Cao, H., Li, X., Gong, X., Yu, X., Li, D., Xie, J., Bai, Y., Zhang, D., Li, X., et al. (2025) · CNS Drugs · doi:10.1007/s40263-024-01145-5 · Cited by 28
Iannuzzo, G., Gentile, M., Bresciani, A., Mallardo, V., Lorenzo, A. D., Merone, P., Cuomo, G., Pacileo, M., Sarullo, F. M., Venturini, E., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071510 · Cited by 27
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Filippatos, T. D., Christopoulou, E. C., & Elisaf, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000523 · Cited by 22
Miñana, G., Núñez, J. E., Bayés‐Genís, A., Revuelta‐López, E., Ríos‐Navarro, C., Núñez, E., Chorro, F. J., López-Lereu, M. P., Monmeneu, J. V., Lupón, J., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12533 · Cited by 25
Current status of lipid management in acute coronary syndrome
Fujisue, K., & Tsujita, K. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.02.004 · Cited by 25
“The inhibition of PCSK9 is expected as a novel strategy in ACS due to its pleiotropic effects [17].”
BackgroundLipid management in ACS: Should we go lower faster?
Gencer, B., & Mach, F. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.871 · Cited by 24
Navarese, E. P., Andreotti, F., Raggi, P., Kołodziejczak, M. M., Buffon, A., Bliden, K. P., Tantry, U. S., Kubica, J., Sardella, G., Lauten, A., et al. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy038 · Cited by 23
“This cascade is also triggered by an increase of the PCSK9 enzyme during an acute coronary syndrome.(22) The involvement of cholesterol crystals in plaque progression and destabilization of atherosclerotic plaques has also been recently recognized as another harbinger of plaque instability; they can perforate the inti…”
BackgroundSelf-citationExploration of PCSK9 as a Cardiovascular Risk Factor
Gurbel, P. A., Navarese, E. P., & Tantry, U. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.779 · Cited by 19
Self-citationSzymański, F. M., Mickiewicz, A., Dzida, G. J., Gorczyca-Głowacka, I., Kozłowski, D., Widecka, K., Krasiński, Z., Kobayashi, A., Hering, D., Mizia‐Stec, K., et al. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0147 · Cited by 22
Sucato, V., Ortello, A., Comparato, F., Novo, G., & Galassi, A. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071882 · Cited by 24
“Recent data suggest that circulating levels of PCSK9 increase within hours of the onset of acute coronary syndrome (SCA) and are associated with increased platelet anti-aggregation, the vulnerability of coronary plaque, elevated inflammatory markers, and higher long-term cardiovascular events [29].”
BackgroundObeid, S. N., Frangieh, A. H., Räber, L., Yousif, N., Gilhofer, T. S., Yamaji, K., Jaguszewski, M. J., Aghlmandi, S., Adams, J., Bockhorn, Y., et al. (2018) · Cardiology Research and Practice · doi:10.1155/2018/9762176 · Cited by 15
Kołodziejczak, M. M., & Navarese, E. P. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.011 · Cited by 15
Self-citationNovel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment
Jigoranu, A. R., Roca, M., Costache, A. D., Mitu, O., Oancea, A. F., Miftode, R.-Ş., Haba, M. Ș. C., Botnariu, G., Maștaleru, A., Gavril, R. S., et al. (2023) · Life · doi:10.3390/life13081639 · Cited by 21
Tiller, C., Holzknecht, M., Lechner, I., Oberhollenzer, F., von der Emde, S., Kremser, T., Gollmann‐Tepeköylü, C., Mayr, A., Bauer, A., Metzler, B., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.123.016482 · Cited by 13
PCSK9 inhibitors in the current management of atherosclerosis
Whayne, T. F. (2016) · Archivos de cardiología de México · doi:10.1016/j.acmx.2016.11.013 · Cited by 11
Navarese, E. P., Kołodziejczak, M. M., Petrescu, A. M., Wernly, B., Lichtenauer, M., Lauten, A., Buffon, A., Wańha, W., Pestrichella, V., Sardella, G., et al. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1474099 · Cited by 10
Self-citationInvestigational drugs in phase II clinical trials for acute coronary syndromes
Rout, A., Sukhi, A., Chaudhary, R., Bliden, K. P., Tantry, U. S., & Gurbel, P. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708324 · Cited by 11
Self-citationKashiwagi, D., Ebisawa, S., Yui, H., Maruyama, S., Nagae, A., Sakai, T., Kato, T., Saigusa, T., Okada, A., Motoki, H., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01680-3 · Cited by 10
Mateos, N., Gómez, M., Homar, A., García-Elías, A., Yáñez, L., Tajes, M., Balaguer, L. M., Blé, M., Cladellas, M., Roqueta, C., et al. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10138-4 · Cited by 9
Pietruszyńska-Reszetarska, A., Pietruszyński, R., & Irzmański, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136924 · Cited by 8
Mensink, F. B., Los, J., ten Cate, T. J. F., Oemrawsingh, R. M., Brouwer, M. A., Messaoudi, S. E., van Royen, N., Cornel, J. H., Riksen, N. P., & van Geuns, R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1061346 · Cited by 7
Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors
Eisen, A., & Giugliano, R. P. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000332 · Cited by 6
Nasso, G., Larosa, C., Bartolomucci, F., Brigiani, M. S., Contegiacomo, G., Demola, M. A., Vignaroli, W., Tripoli, A., Girasoli, C., Lisco, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030907 · Cited by 5
“The anti-inflammatory properties are attributed to the distribution on arterial walls, which promotes inflammation and atherosclerosis [26].”
BackgroundWu, Z.-M., Kan, J., Ye, F., You, W., Wu, X., Tian, N., Lin, S., Ge, Z., Liu, Z., Li, X.-B., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.06.004 · Cited by 5
PCSK9 Inhibition could be Effective for Acute Myocardial Infarction
Gencer, B., & Mach, F. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210804091003 · Cited by 5
LDL-Cholesterol and Atherosclerotic Cardiovascular Disease
Egom, E. E. A. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.100 · Cited by 5
Na, H. R., Kwon, O., Kang, J. K., Kim, Y. H., & Lim, J. Y. (2022) · Trials · doi:10.1186/s13063-022-06398-3 · Cited by 4
Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)
Arnold, N., & Koenig, W. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01163-6 · Cited by 3
Xu, L., Wang, L., Wang, Y., Wang, Y., Jiang, Y., Du, P., Cheng, J., Zhang, C., Wang, R., Jiao, T., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1408760 · Cited by 5
Whayne, T. F. (2016) · International Journal of Angiology · doi:10.1055/s-0036-1597129 · Cited by 4
ESC-Leitlinien 2016 – Dyslipidämien
Sinning, D., & Landmesser, U. (2016) · Herz · doi:10.1007/s00059-016-4505-6 · Cited by 8
Brie, D. M., Mornoş, C., Adam, O., Tîrziu, A., & Brie, A. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186445 · Cited by 8
“Beyond LDL-C lowering, PCSK9 inhibitors contribute to stabilization and regression of atherosclerotic plaques, reducing plaque vulnerability and subsequent ischemic events [42].”
PCSK9 Inhibitors: Lots of Work Done, Lots More to Do
Lauer, M. S. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0422 · Cited by 3
“” In this week's Annals, Navarese and colleagues (2) discuss possibly transformative new drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which are recently approved agents that dramatically reduce low-density lipoprotein (LDL) cholesterol levels.”
BackgroundInfluentialNasso, G., Vignaroli, W., Amodeo, V., Bartolomucci, F., Larosa, C., Contegiacomo, G., Demola, M. A., Girasoli, C., Valenzano, A., Fiore, F., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102987 · Cited by 4
Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
Wang, W., Luo, R., Pei, D. A., Huang, Q., Jin, X., Wu, Y., Xie, M., Wang, S., Sui, X.-Q., & Shen, B. (2023) · Medicine · doi:10.1097/md.0000000000033026 · Cited by 3
“Circulating levels of PCSK9 dynamically increase during ACS as a consequence of cardiac ischemia.[29] A clinical study has revealed that PCSK9 inhibition may confer benefits during ACS through LDL-dependent mechanism.”
BackgroundLuca, L. D., Riccio, C., Navazio, A., Valente, S., Cipriani, M., Corda, M., Nardo, A. D., Francese, G. M., Napoletano, C., Tizzani, E., et al. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad100 · Cited by 3
Intensification of lipid-lowering therapy in patients with acute coronary syndrome
Fedorova, N. V., Sedykh, D. Y., Кашталап, В. В., Chesnokova, L. Y., Gruzdeva, O. V., & Барбараш, О. Л. (2020) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2019-8-4s-121-129 · Cited by 3
Menichelli, D., Galardo, G., Cammisotto, V., Bartimoccia, S., Carnevale, R., Pignatelli, P., & Pastori, D. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0067 · Cited by 2
Xu, L., Wang, Y., Wang, Y., Wang, L., Du, P., Cheng, J. L., Zhang, C., Jiao, T., Xing, L., Tapu, M. S. R., et al. (2024) · Pharmacology · doi:10.1159/000540083 · Cited by 3
Arya, P., Bhandari, U., Sharma, K., & Bansal, P. (2022) · PubMed Central · doi:10.22038/ijbms.2022.60467.13404 · Cited by 3
Is PCSK9 the Key Player in the Ischemia-Reperfusion Match?
Benedetti, A., & Monte, A. D. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017210 · Cited by 2
Inhibidores de PCSK-9, efectos sobre el cLDL e implicaciones futuras: lo que se debe saber
Corral, P., & Ruiz, Á. J. (2017) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2017.06.001 · Cited by 1
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Παναγιωτοπούλου, Ό., Chiesa, S. T., Tousoulis, D. M., & Charakida, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190827151012 · Cited by 1
Update Dyslipidämien – Kommentar zur aktualisierten ESC/EAS-Leitlinie 2016
Sinning, D., & Landmesser, U. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-123146
Landmesser, U., Gohlke, H., Hambrecht, R., Kelm, M., Laufs, U., & Marx, N. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0166-9 · Cited by 1
Szulc-Bagrowska, J., Szepietowski, B., & Lelonek, M. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0033
Sanober, A., Noorjahan, M., Kumari, J. A., Satish, O. S., Sreedevi, N. N., Bhaskar, M. V., Saibaba, K. S. S., & Khan, S. A. (2023) · Journal of Clinical and Preventive Cardiology · doi:10.4103/jcpc.jcpc_20_22
Bellis, A., Mauro, C., Barbato, E., Trimarco, B., & Morisco, C. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00676-8 · Cited by 1
Guanilo, A. D., Moraes, G. J. D., & Knapp, M. (2008) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.181262
Coronary Artery Calcification and Lipid-Lowering Treatment
Kim, J. S. (2025) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2025.0026
Peng, H., Li, X., Zhang, Z., Ma, S., Li, Y., Dai, J., Liu, Q., & Wang, P. (2026) · BMC Neurology · doi:10.1186/s12883-026-04838-0
Jiang, Y., Lin, J., Ma, M., Jiang, M., Wang, H., Xu, J., & Yu, P. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1860137
Lin, X., He, R., Zhang, X., Zeng, Y., Wang, T., Chen, S., Chen, L., & Luo, M. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14199-w
Metadata
- Authors
- Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A.
- Affiliations
- Inova Fairfax Hospital (US)
- From Heinrich Heine University, Düsseldorf, Germany; Systematic Investigation and Research on Interventions and Outcomes MEDICINE and Inova Heart and Vascular Institute, Fairfax, Virginia; Collegium Medicum in Bydgoszcz, University of Nicolaus Copernicus, Toruń, Poland; and Christ Hospital Heart and Vascular Center/Lindner Research Center, Cincinnati, Ohio.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-05-03
- Volume
- 164
- Issue
- 9
- Pages
- 600-607
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2305945749
- Cited by
- 77
- References
- 60
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 7 · 2019: 5 · 2018: 10 · 2017: 8 · 2016: 11
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- PCSK9 inhibitors, monoclonal antibodies, acute coronary syndrome, atherosclerotic plaque vulnerability, plaque composition, plaque vulnerability, dyslipidemia, pharmacokinetics, anti-inflammatory mechanism, antithrombotic mechanism
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Anti-Inflammatory Agents, Antibodies, Monoclonal, Fibrinolytic Agents, Humans, Immunologic Factors, Lipoproteins, LDL, Recurrence, Time Factors, Acute Coronary Syndrome, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.